The first patient in Japan in a new clinical trial that studies regenerative cell medicine enrolled this week.
The trial, which is called the STEMTRA Phase 2 clinical trial is the world’s first global Phase 2 clinical trial of allogeneic stem cell medicine for traumatic brain injury.
“The STEMTRA trial is designed to study the safety, efficacy and tolerability of SB623 in patients with chronic motor impairments persisting at least twelve months following traumatic brain injury. It is being conducted across approximately 30 clinical trial sites in the United States and Japan. The first patient was enrolled in July, 2016, in the United States, and total enrollment is expected to reach 52 patients,” a press release in Business Wire reads.
Traumatic brain injury (TBI) is a complex injury with a broad spectrum of symptoms and disabilities. The impact on a person and his or her family can be devastating. TBI can result from a fall, sports injury, vehicle crash or combat-related incidents. Since our brain defines who we are, the consequences of a brain injury can affect all aspects of a person’s life, including their personality. A brain injury is different from a broken limb or punctured lung. An injury in these areas limit the use of a specific part of your body, but your personality and mental abilities remain unchanged. Most often, these body structures heal and regain their previous function.
Brain injuries do not heal like other injuries, according to traumaticbraininjury.com. Recovery is a functional recovery, based on mechanisms that remain uncertain. No two brain injuries are alike and the consequence of two similar injuries may be very different. Symptoms may appear right away or may not be present for days or weeks after the injury.
One of the consequences of brain injury is that the person often does not realize that a brain injury has occurred.
There are more than 5.3 million people living with disabilities resulting from traumatic brain injury in the United States alone. The trial is designed to demonstrate the efficacy and safety required to address this area of high unmet medical need, according to the press release.
“Damien Bates, Chief Medical Officer and Head of Research at SanBio said this is an important milestone for SanBio. ‘We’ve demonstrated that we can work with regulators to obtain approval for, and rapidly launch, a landmark clinical study for regenerative medicine in Japan,’” the release reads. “Japan grants marketing approval for regenerative medicines earlier than any other country, due to an amendment to the Pharmaceutical Affairs Law in 2014. This amendment introduced a conditional and term-limited Accelerated Approval system for regenerative medicine products and established Japan as a world leader in this field. SanBio intends to utilize Japan’s Accelerated Approval system upon the completion of the STEMTRA study to market SB623 in Japan prior to the rest of the world.”
Main Office Location
Rozek Law Offices, SC
3970 N Oakland Ave Ste 604
Milwaukee, Wisconsin 53211
Additional Client Meeting Location
Rozek Law Offices - Madison
2810 Crossroads Dr Ste 4046
Madison, Wisconsin 53718